Order Article Reprints

Scuteri D, Pierobon D, Pagliaro M, Hamamura K, Hayashi T, Pignolo L, Nicotera P, Bagetta G, Corasaniti MT. Clinical and Market Analysis of NanoBEO: A Public-Worth, Innovative Therapy for Behavioral and Psychological Symptoms of Dementia (BPSD)—Emerging Evidence and Its Implications for a Health Technology Assessment (HTA) and Decision-Making in National Health Systems. Pharmaceutics. 2024; 16(10):1253. https://doi.org/10.3390/pharmaceutics16101253

Scuteri, Damiana, Daniele Pierobon, Martina Pagliaro, Kengo Hamamura, Takafumi Hayashi, Loris Pignolo, Pierluigi Nicotera, Giacinto Bagetta, and Maria Tiziana Corasaniti. 2024. "Clinical and Market Analysis of NanoBEO: A Public-Worth, Innovative Therapy for Behavioral and Psychological Symptoms of Dementia (BPSD)—Emerging Evidence and Its Implications for a Health Technology Assessment (HTA) and Decision-Making in National Health Systems" Pharmaceutics 16, no. 10: 1253. https://doi.org/10.3390/pharmaceutics16101253

Scuteri, D., Pierobon, D., Pagliaro, M., Hamamura, K., Hayashi, T., Pignolo, L., Nicotera, P., Bagetta, G., & Corasaniti, M. T. (2024). Clinical and Market Analysis of NanoBEO: A Public-Worth, Innovative Therapy for Behavioral and Psychological Symptoms of Dementia (BPSD)—Emerging Evidence and Its Implications for a Health Technology Assessment (HTA) and Decision-Making in National Health Systems. Pharmaceutics, 16(10), 1253. https://doi.org/10.3390/pharmaceutics16101253